

30th October 2017 | CannPal Animal Therapeutics Limited ACN: 612 791 518 |  
ASX:CP1

## ***CannPal Advances Research Through Agreement with The University of Queensland***

### **Key Highlights**

- CannPal has entered into a research services agreement with The University of Queensland
- The University of Queensland's TetraQ Research Infrastructure Centre will provide bio-analytical services for CannPal's pharmacokinetic and safety studies
- TetraQ will develop and validate a method for quantification of cannabidiol and tetrahydrocannabinol concentration in dog plasma samples
- The resulting bioanalytical services will be subject to full validation in accordance with regulatory guidelines

---

Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce it has entered into a research services agreement with The University of Queensland.

The University of Queensland's TetraQ Research Infrastructure Centre ("TetraQ") assists research groups within the university and selected external research groups with bioanalytical services.

The research services agreement outlines the terms in which TetraQ will develop and validate a bioanalytical method for simultaneous quantitation of cannabidiol (CBD) and tetrahydrocannabinol (THC) concentrations in dog plasma. TetraQ will subsequently analyze over 850 dog plasma samples in three study phases for CBD and THC concentrations, as part of CannPal's pharmacokinetic and safety studies scheduled for Q1 2018

The bioanalytical studies will be conducted in accordance with OECD Good Laboratory Practice (GLP) and also related United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) bioanalytical method guidances.

CannPal is completing the studies as part of its development plan for CPAT-01, a regulatory approved pain treatment for dogs. The market for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), the most commonly used treatments for pain in companion animals, is worth more than \$1.4b globally, but NSAIDs come with a long list of side effects.

The Company believes that significant value can be created for shareholders by providing veterinarians with a standardized and dosage-controlled medicine using whole plant cannabis extracts, without the side effects associated with current treatments.



CannPal has planned a comprehensive pharmacokinetic and safety study to take place in Q1 2018. The Company is working with leading veterinary research organizations Klifovet, and Invetus Limited, to design and run clinical studies in Australia with TetraQ now contracted to analyse and report on plasma CBD and THC results.

### ***CannPal's Founder and Managing Director Layton Mills***

I'm delighted to have entered into a research agreement with The University of Queensland. TetraQ is highly capable of completing our bioanalytical studies to the highest industry standards and are another crucial research partner that will add significant value to the success of CPAT-01's development plan.

### ***About CannPal Animal Therapeutics***

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.

### ***About TetraQ***

TetraQ is a research infrastructure centre within the University of Queensland based in Brisbane, Australia. Since 2005 TetraQ has operated as an independent CRO offering a range of high-quality, preclinical and clinical testing services to the global pharmaceutical, bio-technology and veterinary industries. Its accredited laboratories and quality system have successfully passed multiple audits by national and international clients and regulatory authorities.

To learn more please visit: [www.cannpal.com](http://www.cannpal.com)

**Baden Bowen** *Company Secretary, CannPal Animal Therapeutics*

**END**

---

### **For further information, please contact:**

#### **CannPal**

Layton Mills  
Founder and Managing Director  
M: +61 431 302 667  
E: [layton@cannpal.com](mailto:layton@cannpal.com)

#### **Media enquiries**

Julia Maguire  
The Capital Network  
M: +61 419 815 386  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)



**@CannPalAT**



**facebook.com/CannPal**

